![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Medgenics(Regs) | LSE:MEDG | London | Ordinary Share | COM SHS USD0.0001 (REGS) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 302.50 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Medgenics, Inc. ('Medgenics' or the 'Company') Blocklisting Interim Review 4 June 2008 1. Name of company: Medgenics, Inc. 2. Name of scheme: Warrants and Options under the Company's Share Incentive Schemes 3. Period of return: From To 4 December 2007 3 June 2008 4. Number and class of securities not issued under the scheme at the beginning of the period: 20,818,683 Common Shares 5. Number of securities issued under scheme during period: 2,462,050 Common Shares following the due exercise of Warrants issued by the Company (2,241,050 Common Shares pursuant to L Warrants, 173,276 Common Shares pursuant to W Warrants and 47,724 Common Shares pursuant to RW Warrants). 6. Balance under scheme of securities not yet issued at end of period: 18,356,633 Common Shares 7. Number and class of securities originally admitted and the date of admission: 20,818,683 Common Shares admitted under the block admission on 4 December 2007. Following the above issues during the period and subsequent to the issue of 142,609 Common Shares as announced on 22 April 2008, the total number of shares in issue is 106,698,076, the percentage of shares not in public hands is 31.7 per cent. and the shareholders who hold more than three per cent. of the issued share capital are as follows: Name Number of % of Issued Common Share Shares Capital Lord Leonard Steinberg 14,484,725 13.6% Joel Kanter * 8,998,566 8.4% Alta California Partners III, L.P. 7,412,472 6.9% Platinum-Montaur Life Sciences 1, LLC 7,190,208 6.7% Vision Opportunity Master Fund, Ltd. 7,094,851 6.6% Koor Corporate Venture Capital, L.P. 5,393,821 5.1% Chicago Investments Inc.** 4,400,807 4.1% CIBC Trust Company (Bahamas)Ltd. ** 3,605,985 3.4% Notes: * Included in the interests of Joel Kanter are his interests in: (i) 949,226 Common Shares held by the Kanter Family Foundation, an Illinois not- for-profit corporation of which Mr. Kanter is the President and is a Director; (ii) 3,605,985 Common Shares held by CIBC Trust Company (Bahamas) Limited ("CIBC"). CIBC is the trustee of Settlement T-555 (the "CIBC Trust"). The CIBC Trust was established for the benefit of various descendants of (i) Helen and Henry Krakow, and (ii) Beatrice and Morris Kanter. Mr. Kanter is a discretionary beneficiary of the CIBC Trust. Sole voting and investment control of the Common Shares owned by the CIBC Trust is vested in CIBC as trustee of the CIBC Trust; (iii) 4,400,807 Common Shares held by Chicago Investments, Inc. ("CII"). CII is a majority-owned subsidiary of Chicago Holdings, Inc. ("CHI"). CHI is majority owned by various trusts (together the "Kanter Trusts") established for the benefit of various descendants of (i) Helen and Henry Krakow, and (ii) Beatrice and Morris Kanter. Joel Kanter is a discretionary beneficiary of some, but not all, of the Kanter Trusts. Sole voting and investment control of the Common Shares owned by CII is vested in Mr. Kanter's brother, Joshua Kanter, as President of CII; and (iv) 42,548 Common Shares held by Chicago Private Investments, Inc ("CPI"). CPI is a wholly owned subsidiary of The Holding Company ("THC"). THC is owned by Kanter Trusts. Sole voting and investment control of the shares of the Company owned by CPI is vested in Mr. Kanter's brother, Joshua Kanter, as President of CPI. For the purposes of applicable US Securities Laws and regulations, Mr. Kanter disclaims all beneficial and pecuniary interest to the Common Shares held by CII and CPI and the CIBC Trust. Such disclaimer does not affect Mr. Kanter's status as a discretionary beneficiary under the Kanter Trusts or the CIBC Trust. ** Included in the interests of Joel Kanter. For further information, contact: Medgenics, Inc. +972 4 902 8900 Dr. Andrew L. Pearlman Citigate Dewe Rogerson +44 207 638 9571 Dr. Mark Swallow Jonathan Shillington (Global Consulting Group) Blomfield Corporate Finance Limited +44 207 489 4500 James Pinner Alan MacKenzie SVS Securities plc +44 207 638 5600 Peter Manfield Ian Callaway
1 Year Medgenics(Regs) Chart |
1 Month Medgenics(Regs) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions